The mergers and acquisitions market is showing vital signs again, and the financial press is predictably breathless about it. Deal volumes have ticked upward, a handful of marquee transactions have crossed the finish line, and investment bankers are dusting off pitch decks that have been gathering cobwebs since 2023. But the gap between "activity" and "recovery" remains considerable, and conflating the two is a reliable way to misread where corporate dealmaking actually stands.
The arithmetic of caution
The M&A drought of 2023-2024 wasn't a mystery. Rising interest rates made leveraged buyouts expensive, regulatory scrutiny under the previous administration turned routine approvals into multi-year ordeals, and valuation gaps between buyers and sellers proved unbridgeable when both sides remembered what multiples looked like in 2021. None of these conditions has fully reversed. Rates have stabilized but not collapsed. Antitrust enforcement has softened rhetorically but the FTC and DOJ still have teeth. And founders who watched their peers sell at thirty times revenue are not psychologically prepared to accept twelve.
What has changed is time. Companies that could afford to wait have run out of patience. Strategic acquirers sitting on cash are under pressure from boards to deploy it. Private equity firms facing fund-life deadlines need to exit portfolio companies whether the market cooperates or not. This is dealmaking driven by calendar constraints, not conviction.
The sectors moving first
Technology and healthcare remain the most active verticals, which surprises no one. Tech companies with strong balance sheets are using the moment to consolidate weaker competitors at discounts that would have been unthinkable three years ago. Healthcare, perpetually fragmented and perpetually ripe for roll-ups, continues its slow-motion consolidation regardless of macro conditions. Energy and infrastructure deals are picking up as well, driven by the capital requirements of data centers and grid modernization—sectors where strategic logic overwhelms valuation quibbles.
What's notably absent is the return of mega-deals. The billion-dollar-plus transactions that defined the 2020-2021 frenzy remain scarce. Financing for truly large LBOs is still expensive, and the regulatory gauntlet for transformative combinations remains daunting. The deals getting done are mid-market, bolt-on, and strategic—sensible but not spectacular.
Our take
The M&A market is defrosting, not recovering. Bankers will call this a turning point because their compensation depends on volume, and CEOs will announce deals because boards reward action over patience. But the underlying conditions that suppressed dealmaking—elevated capital costs, regulatory uncertainty, and persistent valuation disagreements—have moderated rather than resolved. Expect more activity, yes. Expect a return to 2021's euphoria, no. The smart money is doing deals because specific opportunities justify specific prices, not because the market has declared a new cycle. That distinction matters.
